A client has been prescribed transdermal fentanyl for chronic pain. Which statement would be most appropriate to provide during client teaching?

A. A hydrophilic medication that is not able to cross the blood-brain barrier: Hydrophilic drugs do not easily pass through lipid membranes like the blood-brain barrier, but this property does not define a depot medication which are characterized by prolonged release, not solubility or blood-brain barrier permeability.

B. An intramuscular injection that is released slowly over a long period of time: Depot medications are typically given intramuscularly or subcutaneously and formulated to release the active drug gradually. This provides sustained therapeutic effects over days or weeks, improving adherence and maintaining stable drug levels.

C. A tablet that is placed under the tongue in order to be absorbed quickly: Sublingual tablets are designed for rapid absorption through the oral mucosa, bypassing first-pass metabolism. This route provides immediate effects, which is the opposite of the slow, sustained action seen with depot medications.

D. A capsule that is formulated for a sustained release: Although sustained-release capsules also allow gradual drug absorption, they are taken orally and work through controlled dissolution. Depot medications differ in that they are injectable and create a long-lasting drug reservoir within body tissues.

A. Enteral: Medications given by the enteral route (oral, gastric, or intestinal) pass through the gastrointestinal tract and are transported to the liver via the portal circulation, where they undergo first-pass metabolism. This reduces the amount of active drug that reaches systemic circulation.

B. Transdermal: Drugs absorbed through the skin enter directly into systemic circulation, bypassing the gastrointestinal tract and the liver initially. This allows for a steady release of medication without significant first-pass metabolism, making it a useful route for drugs requiring sustained blood levels.

C. Intravaginal: Vaginal administration provides local and systemic effects by allowing drug absorption through the mucosa directly into the bloodstream. Since it avoids the hepatic portal system, this route reduces first-pass metabolism and enhances systemic bioavailability.

D. Subcutaneous: Medications injected into subcutaneous tissue are absorbed into systemic circulation through capillaries and lymphatic vessels. This route bypasses the gastrointestinal system and liver initially, minimizing first-pass metabolism and ensuring more predictable drug levels.

E. Intranasal: Drugs administered intranasally are absorbed through the nasal mucosa directly into systemic circulation. This route avoids the liver’s first-pass effect, providing rapid onset of action and making it suitable for medications requiring quick therapeutic effects.